Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Jakesz, R; Hausmaninger, H; Haider, K; Kubista, E; Samonigg, H; Gnant, M; Manfreda, D; Tschurtschenthaler, G; Kolb, R; Stierer, M; Fridrik, M; Mlineritsch, B; Steindorfer, P; Mittlböck, M; Steger, G.
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
J Clin Oncol. 1999; 17(6):1701-1709
Doi: 10.1200/JCO.1999.17.6.1701
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: To evaluate the outcome in patients with stage It hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival. Patients and Methods: A total of 613 patients were randomized to receive either low-dose chemotherapy (doxorubicin 20 mg/m(2) and vincristine 1 mg/m(2) on day 1; cyclophosphamide 300 mg/m(2); methotrexate 25 mg/m2; and fluorouracil 600 mg/m(2) on days 29 and 36 intravenously) or no chemotherapy in addition to 20 mg of tamoxifen orally for 2 years. A third group without any treatment (postmenopausal patients only) was terminated after the accrual of 79 patients due to ethical reasons. Results: After a median follow-up period of 7.5 years, the addition of chemotherapy did not improve the outcome in patients as compared with those treated with tamoxifen alone, neither with respect to disease-free nor overall survival. Multivariate analysis of prognostic factors for disease-free survival revealed menopausal status, in addition to nodal status, progesterone receptor, and histologic grade as significant. Both untreated postmenopausal and tamoxifen-treated premenopausal patients showed identical prognoses significantly inferior to the tamoxifen-treated postmenopausal cohort. Prognostic factors for overall survival in the multivariate analysis showed nodal and tumor stage, tumor grade, and hormone receptor level as significant. Conclusion: Low-dose chemotherapy in addition ta tamoxifen does not improve the prognosis of stage II breast cancer patients with hormone-responsive tumors. Tamoxifen-treated postmenopausal patients show a significantly better prognosis than premenopausal patients, favoring the hypothesis of a more pronounced effect of tamoxifen in the older age groups. (C) 1999 by American Society of Clinical Oncology.
- Find related publications in this database (using NLM MeSH Indexing)
- Age Factors -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality
- Carcinoma - diagnosis Carcinoma - drug therapy Carcinoma - metabolism Carcinoma - mortality
- Cyclophosphamide - administration & dosage
- Disease-Free Survival -
- Doxorubicin - administration & dosage
- Female -
- Fluorouracil - administration & dosage
- Humans -
- Lymphatic Metastasis -
- Methotrexate - administration & dosage
- Middle Aged -
- Neoplasm Recurrence, Local -
- Prognosis -
- Receptors, Estrogen - metabolism
- Receptors, Progesterone - metabolism
- Recurrence -
- Survival Rate -
- Tamoxifen - administration & dosage Tamoxifen - therapeutic use
- Vincristine - administration & dosage